Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk HCQ for COVID-19  Aghajani et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 991 patients in Iran Lower mortality with HCQ (not stat. sig., p=0.087) c19hcq.org Aghajani et al., J. Medical Virology, Apr 2021 Favors HCQ Favors control

Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19

Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053
Apr 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
Although the 19% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 250 mortality results to date.
Study covers remdesivir, favipiravir, and HCQ.
risk of death, 19.5% lower, HR 0.81, p = 0.09, treatment 553, control 438, multivariate Cox proportional regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aghajani et al., 29 Apr 2021, retrospective, Iran, peer-reviewed, 7 authors.
This PaperHCQAll
Decreased in‐hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID‐19
Mohammad Haji Aghajani, Omid Moradi, Hossein Amini, Hamed Azhdari Tehrani, Elham Pourheidar, Mohammad M Rabiei, Mohammad Sistanizad
Journal of Medical Virology, doi:10.1002/jmv.27053
Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID-19) are related to the higher mortality rate. Because of limited data on the antiplatelet effect, we aimed to evaluate the impact of aspirin add-on therapy on the outcome of the patients hospitalized due to severe COVID-19. In this cohort study, patients with a confirmed diagnosis of severe COVID-19 admitted to Imam Hossein Medical
The main limitations of our study were the retrospective pattern of the study and lack of data about the probable adverse effect of aspirin, such as bleeding components. In conclusion, based on the result of our study, in patients who received aspirin, a relevant underlying condition such as hypertension, diabetes, and coronary artery disease was more prevalent. These patients had a more severe course of the disease and a longer duration of hospitalization. By adjustment of the effect of underlying conditions and confounding factors, aspirin use in severe hospitalized COVID-19 patients is independently associated with a 25% decrease in mortality rate. So, by considering all the probable described mechanisms and the results of other studies in this regard, we recommend using aspirin during the hospital stay for all patients with the diagnosis of severe COVID-19. ACKNOWLEDGMENT This study was supported via the Deputy of research and technology, Shahid Beheshti University of Medical Sciences, Iran. No specific grants from funding agencies, commercial, and non-profit sectors were received. CONFLICT OF INTERESTS The authors declare that there are no conflicts of interest. AUTHOR CONTRIBUTIONS
References
Abou-Ismail, Diamond, Kapoor, Arafah, Nayak, The hypercoagulable state in COVID-19: incidence, pathophysiology, and management, Thromb Res, doi:10.1016/j.thromres.2020.06.029
Aghajani, Moradi, Amini, Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19, J Med Virol
Barrett, Moore, Yaffe, Moore, ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment, J Thromb Haemost, doi:10.1111/jth.14860
Carfora, Spiniello, Ricciolino, Anticoagulant treatment in COVID-19: a narrative review, J Thromb Thrombolysis, doi:10.1007/s11239-020-02242-0
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and inhospital mortality in hospitalized patients with COVID-19
Cicci, Iyer, Clarke, Mazzella, Aspirin for the primary prevention of cardiovascular disease: a review of the literature and considerations for clinical practice, Cardiol Rev, doi:10.1097/CRD.0000000000000297
Godino, Scotti, Maugeri, Antithrombotic therapy in patients with COVID-19?-Rationale and evidence, Int J Cardiol, doi:10.1016/j.ijcard.2020.09.064
Levi, Thachil, Iba, Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Hematol, doi:10.1016/S2352-3026(20)30145-9
Mcfadyen, Stevens, Peter, The emerging threat of (Micro) thrombosis in COVID-19 and its therapeutic implications, Circ Res, doi:10.1161/CIRCRESAHA.120.317447
Mulcahy, Ghulam-Smith, Mamidi, Oropharyngeal hemorrhage in patients with COVID-19: a multi-institutional case series, Am J Otolaryngol, doi:10.1016/j.amjoto.2020.102691
Porfidia, Valeriani, Pola, Porreca, Rutjes et al., Venous thromboembolism in patients with COVID-19: systematic review and meta-analysis, Thromb Res, doi:10.1016/j.thromres.2020.08.020
Rapkiewicz, Mai, Carsons, Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100434
Sivaloganathan, Ladikou, Chevassut, COVID-19 mortality in patients on anticoagulants and antiplatelet agents, Br J Haematol, doi:10.1111/bjh.16968
Vasanthakumar, Beta-adrenergic blockers as a potential treatment for COVID-19 patients, BioEssays, doi:10.1002/bies.202000094
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Yuan, Chen, Li, Chen, Wang et al., Mortality and prehospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease, J Cell Mol Med, doi:10.1111/jcmm.16198
Zhang, Zhu, Cai, Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res, doi:10.1161/CIRCRESAHA.120.317134
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
{ 'DOI': '10.1002/jmv.27053', 'ISSN': ['0146-6615', '1096-9071'], 'URL': 'http://dx.doi.org/10.1002/jmv.27053', 'alternative-id': ['10.1002/jmv.27053'], 'archive': ['Portico'], 'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2021-02-14'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 1, 'value': '2021-04-26'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 2, 'value': '2021-05-08'}], 'author': [ { 'affiliation': [ { 'name': 'Prevention of Cardiovascular Disease Research Center, Imam ' 'Hossein Hospital Shahid Beheshti University of Medical Sciences ' 'Tehran Iran'}], 'family': 'Haji Aghajani', 'given': 'Mohammad', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0001-5754-535X', 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, School of Pharmacy Shahid ' 'Beheshti University of Medical Sciences Tehran Iran'}], 'authenticated-orcid': False, 'family': 'Moradi', 'given': 'Omid', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, School of Pharmacy Shahid ' 'Beheshti University of Medical Sciences Tehran Iran'}], 'family': 'Amini', 'given': 'Hossein', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Hematology and Medical Oncology Shahid Beheshti ' 'University of Medical Sciences Tehran Iran'}], 'family': 'Azhdari Tehrani', 'given': 'Hamed', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Hematology and Medical Oncology Shahid Beheshti ' 'University of Medical Sciences Tehran Iran'}], 'family': 'Pourheidar', 'given': 'Elham', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-7146-170X', 'affiliation': [ { 'name': 'Clinical Research Development Unit of Loghman Hakim Hospital ' 'Shahid Beheshti University of Medical Sciences Tehran Iran'}], 'authenticated-orcid': False, 'family': 'Rabiei', 'given': 'Mohammad M.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Prevention of Cardiovascular Disease Research Center, Imam ' 'Hossein Hospital Shahid Beheshti University of Medical Sciences ' 'Tehran Iran'}, { 'name': 'Department of Clinical Pharmacy, School of Pharmacy Shahid ' 'Beheshti University of Medical Sciences Tehran Iran'}], 'family': 'Sistanizad', 'given': 'Mohammad', 'sequence': 'additional'}], 'container-title': ['Journal of Medical Virology'], 'content-domain': {'crossmark-restriction': True, 'domain': ['onlinelibrary.wiley.com']}, 'created': {'date-parts': [[2021, 4, 29]], 'date-time': '2021-04-29T10:11:32Z', 'timestamp': 1619691092000}, 'deposited': { 'date-parts': [[2021, 7, 16]], 'date-time': '2021-07-16T20:42:02Z', 'timestamp': 1626468122000}, 'indexed': {'date-parts': [[2022, 1, 13]], 'date-time': '2022-01-13T19:48:55Z', 'timestamp': 1642103335659}, 'is-referenced-by-count': 9, 'issn-type': [{'type': 'print', 'value': '0146-6615'}, {'type': 'electronic', 'value': '1096-9071'}], 'issue': '9', 'issued': {'date-parts': [[2021, 5, 8]]}, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2021, 9]]}}, 'language': 'en', 'license': [ { 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 5, 8]], 'date-time': '2021-05-08T00:00:00Z', 'timestamp': 1620432000000}}, { 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 5, 8]], 'date-time': '2021-05-08T00:00:00Z', 'timestamp': 1620432000000}}], 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27053', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.27053', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27053', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '311', 'original-title': [], 'page': '5390-5395', 'prefix': '10.1002', 'published': {'date-parts': [[2021, 5, 8]]}, 'published-online': {'date-parts': [[2021, 5, 8]]}, 'published-print': {'date-parts': [[2021, 9]]}, 'publisher': 'Wiley', 'reference': [ {'DOI': '10.1111/bjh.16968', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_2_1'}, { 'article-title': 'Aspirin use is associated with decreased mechanical ventilation, ICU ' 'admission, and in‐hospital mortality in hospitalized patients with ' 'COVID‐19 [published online ahead of print]', 'author': 'Chow JH', 'journal-title': 'Anesth Analg', 'key': 'e_1_2_8_3_1', 'year': '2020'}, {'DOI': '10.1007/s11239-020-02242-0', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_4_1'}, { 'DOI': '10.1016/j.thromres.2020.06.029', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_5_1'}, { 'DOI': '10.1016/j.thromres.2020.08.020', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_6_1'}, { 'DOI': '10.1016/j.amjoto.2020.102691', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_7_1'}, { 'DOI': '10.1016/j.ijcard.2020.09.064', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_8_1'}, { 'DOI': '10.1097/CRD.0000000000000297', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_9_1'}, {'DOI': '10.1001/jama.2020.2648', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_10_1'}, { 'DOI': '10.1016/S0140-6736(20)30566-3', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_11_1'}, {'DOI': '10.1002/bies.202000094', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_12_1'}, { 'DOI': '10.1161/CIRCRESAHA.120.317134', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_13_1'}, { 'DOI': '10.1016/S2352-3026(20)30145-9', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_14_1'}, { 'DOI': '10.1161/CIRCRESAHA.120.317447', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_15_1'}, { 'DOI': '10.1016/j.eclinm.2020.100434', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_16_1'}, {'DOI': '10.1111/jth.14860', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_17_1'}, {'DOI': '10.1111/jcmm.16198', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_18_1'}], 'reference-count': 17, 'references-count': 17, 'relation': {}, 'score': 1, 'short-container-title': ['J Med Virol'], 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Virology'], 'subtitle': [], 'title': [ 'Decreased in‐hospital mortality associated with aspirin administration in hospitalized ' 'patients due to severe COVID‐19'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'volume': '93'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit